CA2144425A1 - Microparticules portant des antigenes et leur utilisation pour l'introduction de reponses humorales ou cellulaires - Google Patents

Microparticules portant des antigenes et leur utilisation pour l'introduction de reponses humorales ou cellulaires

Info

Publication number
CA2144425A1
CA2144425A1 CA002144425A CA2144425A CA2144425A1 CA 2144425 A1 CA2144425 A1 CA 2144425A1 CA 002144425 A CA002144425 A CA 002144425A CA 2144425 A CA2144425 A CA 2144425A CA 2144425 A1 CA2144425 A1 CA 2144425A1
Authority
CA
Canada
Prior art keywords
humoral
microparticules
introduction
cell responses
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002144425A
Other languages
English (en)
Other versions
CA2144425C (fr
Inventor
Christine Gengoux
Claude Leclerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Christine Gengoux
Claude Leclerc
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christine Gengoux, Claude Leclerc, Institut Pasteur filed Critical Christine Gengoux
Publication of CA2144425A1 publication Critical patent/CA2144425A1/fr
Application granted granted Critical
Publication of CA2144425C publication Critical patent/CA2144425C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Abstract

Utilisation pour l'induction d'une réponse immunitaire de microparticules en matériau synthétique polymère portant en surface une ou plusieurs protéines liées de manière covalente pouvant porter un ou plusieurs épitopes, les densités de la ou des protéines à la surface des microparticules, ainsi que leurs poids moléculaires, étant ajustées afin d'orienter la réponse immunitaire vers l'induction d'une réponse humorale et cellulaire ou vers l'induction d'une réponse majoritairement cellulaire. Les microparticules ont un diamètre moyen compris entre environ 0,25 et environ 1,5 .mu.m.
CA002144425A 1992-09-11 1993-09-13 Microparticules portant des antigenes et leur utilisation pour l'introduction de reponses humorales ou cellulaires Expired - Lifetime CA2144425C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9210879A FR2695563B1 (fr) 1992-09-11 1992-09-11 Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
FR9210879 1992-09-11
PCT/FR1993/000876 WO1994006472A1 (fr) 1992-09-11 1993-09-13 Microparticules portant des antigenes et leur utilisation pour l'induction de reponses humorales ou cellulaires

Publications (2)

Publication Number Publication Date
CA2144425A1 true CA2144425A1 (fr) 1994-03-31
CA2144425C CA2144425C (fr) 2008-12-30

Family

ID=9433435

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002144425A Expired - Lifetime CA2144425C (fr) 1992-09-11 1993-09-13 Microparticules portant des antigenes et leur utilisation pour l'introduction de reponses humorales ou cellulaires

Country Status (12)

Country Link
US (1) US5871747A (fr)
EP (1) EP0662000B1 (fr)
AT (1) ATE194496T1 (fr)
AU (1) AU4966693A (fr)
CA (1) CA2144425C (fr)
DE (1) DE69329030T2 (fr)
DK (1) DK0662000T3 (fr)
ES (1) ES2149210T3 (fr)
FR (1) FR2695563B1 (fr)
GR (1) GR3034550T3 (fr)
PT (1) PT662000E (fr)
WO (1) WO1994006472A1 (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313975A1 (de) * 1993-04-28 1994-11-03 Cytech Biomedical Inc Immunisierungsmittel und Affinitätschromatographie-Trägermaterial
DK0686030T3 (da) * 1993-12-23 2001-06-25 Rmf Dictagene Sa Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler
ES2108614B1 (es) * 1995-07-12 1998-07-16 Oncina Fco Javier Martin Vacunas polimerizadas.
EP0991403B1 (fr) * 1997-01-30 2003-04-02 Chiron Corporation Utilisation de microparticules contenant un antigene adsorbe dans le but de stimuler les reponses immunitaires
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6544751B1 (en) * 1997-04-08 2003-04-08 Pall Corporation Methods of harvesting rare cells from blood products
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
EP0996717B1 (fr) 1997-08-05 2005-12-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Nouvel antigene immunoprotecteur contre la grippe a et son utilisation dans la vaccination
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
WO2000032227A2 (fr) * 1998-11-30 2000-06-08 Cytos Biotechnology Ag Presentation moleculaire ordonnee d'antigenes, procede de preparation et utilisation
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2002533124A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
WO2000039303A2 (fr) 1998-12-31 2000-07-06 Chiron Corporation Polypeptides vih env modifies
CA2358385C (fr) * 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
US6929907B2 (en) 1999-12-31 2005-08-16 North Carolina State University Methods and compositions for determining the purity of chemically synthesized nucleic acids
WO2001079300A1 (fr) * 2000-04-12 2001-10-25 Genetics Institute, Llc. Antigene a liaison de surface reliant des portions d'anticorps se liant au ctla-4 et au cd28 et applications
CA2407897A1 (fr) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Jeu ordonne d'antigenes moleculaires
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
WO2002026209A2 (fr) * 2000-09-28 2002-04-04 Chiron Corporation Microparticules de transport d'acides nucleiques heterologues
JP2004509914A (ja) * 2000-09-28 2004-04-02 カイロン　コーポレイション 微粒子組成物およびその製造方法
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6887857B2 (en) 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
CA2452690C (fr) * 2001-06-29 2016-08-16 Veri-Q, Inc. Procedes et compositions pour determiner la purete d'acides nucleiques synthetises par voie chimique et les purifier
WO2003004620A2 (fr) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
CA2452119C (fr) * 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
FR2828648A1 (fr) * 2001-08-16 2003-02-21 Adam Bouaziz Constitution d'un vaccin extractible a partir d'un insert immunogene.
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2005521380A (ja) * 2001-08-31 2005-07-21 カイロン コーポレイション 抗原性ｂ型ｈｉｖポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
WO2003024480A2 (fr) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag Activation in vivo de cellules presentant un antigene en vue d'augmenter les reponses immunes induites par des particules de type virus
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
WO2004006959A1 (fr) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Compositions pour doses liquides d'agents actifs nanoparticulaires stables
CA2489410C (fr) * 2002-07-17 2015-01-13 Cytos Biotechnology Ag Reseaux d'antigenes moleculaires
KR20120041739A (ko) 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
WO2004085635A1 (fr) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Conjugues de particules d'aspect viral d'analogues du peptide melan-a
CA2528007C (fr) * 2003-06-02 2012-03-27 Chiron Corporation Compositions immunogenes basees sur des microparticules comprenant des antigenes contenant de l'anatoxine adsorbee et des polysaccharides
CN1905903A (zh) * 2004-01-20 2007-01-31 赛托斯生物技术公司 生长素释放肽－载体偶联物
WO2007001448A2 (fr) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Particules polymeres revetues a diffusion regulee comme vecteurs efficaces d'administration par voie orale de produits biopharmaceutiques
BRPI0606479A (pt) 2005-01-19 2008-03-11 Vaxinnate Corp composições; proteìnas de fusão; polipepitìdeos; e métodos para estimular uma resposta imune em um indivìduo
WO2007041190A2 (fr) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Systeme d'administration a base de polymere pour immunotherapie anticancereuse
RU2472812C2 (ru) * 2005-12-05 2013-01-20 НИТТО ДЕНКО КОРПОРЭЙШН (Джэпэн/Джэпэн) Конъюгаты полиглутамат-аминокислота и способы
EP1973608A1 (fr) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Particules emballees avec des acides nucleiques immunostimulateurs pour le traitement de l hypersensibilite
WO2007070682A2 (fr) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology Systeme de criblage de particules
CN106237316A (zh) * 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
CA2648099C (fr) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc Systeme pour l'administration ciblee d'agents therapeutiques
CA2652280C (fr) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymeres pour particules fonctionnelles
DK2032592T3 (da) 2006-06-12 2013-09-02 Cytos Biotechnology Ag Fremgangsmåder til pakning af oligonukleotider til virus-lignende partikler af rna-bakteriofager
WO2007150030A2 (fr) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Synthèse microfluidique de nanoparticules organiques
WO2008019142A2 (fr) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Systèmes oligonucléotidiques pour une administration intracellulaire ciblée
WO2008147456A2 (fr) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Systèmes d'administration de médicaments en utilisant des fragments fc
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2134830A2 (fr) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Bioréacteur oscillant pour la culture de cellules
WO2008124639A2 (fr) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Fractions de ciblage de poly (acide aminé)
CN104800856A (zh) * 2007-04-10 2015-07-29 日东电工株式会社 多功能聚谷氨酸盐药物载体
JP2010526917A (ja) * 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
WO2008141107A2 (fr) 2007-05-09 2008-11-20 Nitto Denko Corporation Compositions contenant un composé hydrophobe et un conjugué polyamino acide
JP2010528122A (ja) * 2007-05-09 2010-08-19 日東電工株式会社 白金薬剤と結合されたポリマー
ES2627292T3 (es) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
CA2716662A1 (fr) * 2008-03-06 2009-03-11 Nitto Denko Corporation Conjugues polymere paclitaxel et procede de traitement du cancer
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP2711021B1 (fr) * 2008-05-02 2016-03-09 BliNK Therapeutics Limited Produits et procédés permettant de stimuler une réponse immunitaire
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
BRPI1011836A2 (pt) * 2009-04-21 2017-05-16 Selecta Biosciences Inc imunonanoterapêuticos que fornecem uma resposta induzida por th1
AU2010254551B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
CA2793959C (fr) 2010-03-25 2019-06-04 Oregon Health & Science University Glycoproteines du cmv et vecteurs recombines
CA2798323A1 (fr) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Selection de dose de nanovecteurs synthetiques avec adjuvant
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
CN103429232B (zh) 2010-11-12 2016-03-16 盖茨咨询和项目管理公司 修饰的免疫调节粒子
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
CA3211102A1 (fr) 2012-06-21 2013-12-27 Northwestern University Particules conjuguees a des peptides
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
JP6725413B2 (ja) 2013-03-13 2020-07-15 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 炎症の治療のための免疫修飾粒子
EP3033102B2 (fr) 2013-08-13 2023-12-20 Northwestern University Particules conjuguées à un peptide
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3303585A4 (fr) 2015-06-03 2018-10-31 Board of Regents of the University of Nebraska Traitement des données d'une séquence d'adn utilisant un adn monocaténaire
WO2018031771A1 (fr) 2016-08-11 2018-02-15 University Of Iowa Research Foundation Nanoparticules inhibitrice de camkii cationique pour le traitement de l'asthme allergique.
WO2021076794A1 (fr) 2019-10-15 2021-04-22 Cornell University Procédés de modulation du niveau d'expression à partir d'une cassette d'expression de thérapie génique
WO2021076941A1 (fr) 2019-10-16 2021-04-22 Cornell University Thérapie génique pour la maladie d'alzheimer
WO2021086973A2 (fr) 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation pour l'administration d'un gène de lubricine
JP2023502515A (ja) 2019-11-25 2023-01-24 コーネル・ユニバーシティー Ａｐｏｅ遺伝子療法
CN115835886A (zh) 2020-04-23 2023-03-21 衣阿华大学研究基金会 Gper蛋白水解靶向嵌合体
US20230293678A1 (en) 2020-08-21 2023-09-21 Aliasger K. Salem Cationic nanoparticle adjuvants
US20230414787A1 (en) 2020-08-27 2023-12-28 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
EP4340894A1 (fr) 2021-05-21 2024-03-27 University Of Iowa Research Foundation Particules contenant un antioxydant et procédés d'utilisation
WO2022271951A1 (fr) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Formulations à libération prolongée comprenant un modulateur sélectif du récepteur des androgènes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine

Also Published As

Publication number Publication date
FR2695563A1 (fr) 1994-03-18
FR2695563B1 (fr) 1994-12-02
ATE194496T1 (de) 2000-07-15
CA2144425C (fr) 2008-12-30
GR3034550T3 (en) 2001-01-31
DE69329030T2 (de) 2001-03-22
EP0662000B1 (fr) 2000-07-12
ES2149210T3 (es) 2000-11-01
DE69329030D1 (de) 2000-08-17
EP0662000A1 (fr) 1995-07-12
WO1994006472A1 (fr) 1994-03-31
US5871747A (en) 1999-02-16
PT662000E (pt) 2000-12-29
DK0662000T3 (da) 2000-11-13
AU4966693A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
CA2144425A1 (fr) Microparticules portant des antigenes et leur utilisation pour l'introduction de reponses humorales ou cellulaires
CA2104899A1 (fr) Anticorps contre Plasmodium falciparum
FR2406584A1 (fr) Dispositifs de support portes et guides par une pellicule d'air
DE3380697D1 (en) Monoclonal antibody
NZ301290A (en) Mycobacterial proteins, micro-organisms producing same and vaccines thereof
MC2039A1 (fr) Proteine ayant un ou plusieurs determinants immuno-reactifs et/ou antigeniques d'un antigene de surface d'eimeria,utilisation et procede de preparation
CA2122613A1 (fr) Administration ciblee d'un vecteur viral a des cellules de mammifere
IT1240793B (it) Procedimento e dispositivo per il controllo di qualita' di contenitori aperti da un lato, quali ad esempio bicchieri, coni tazze e simili.
HUP9904620A3 (en) Purified sperm surface antigen,monoclonal antibody therefor and applications therefor
CA2240296A1 (fr) Inhibiteur de la proliferation des cellules endotheliales, et procede d'utilisation de celui-ci
EP0754229A1 (fr) L'alfamine, une proteine albuminoide serique humaine
CA2193870A1 (fr) Antigene fusionne de treponema pallidum et epreuve de detection des anticorps anti-treponeme pallidum faisant appel audit antigene fusionne
ATE71149T1 (de) Monoklonale antikoerper.
IT8524004V0 (it) Dispositivo per smistare pacchi e simili su nastri di convogliatori degli stessi.
WO1999009167A8 (fr) Genes de classe i mhc porcins et utilisations de ces genes
AU6681494A (en) Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation thereof
IT8785542A0 (it) Dispositivo per la sigillatura di buste in materia plastica o simili.
CA2081879A1 (fr) Anticorps monoclonaux des polyacrilates
EP0345559A3 (fr) Variants du HIV-2
MX9700208A (es) Preparacion de proteina antigena y pruebas inmunologicas de helicobacter pylori.
IT8228973V0 (it) Dispositivo di congiunzione, in particolare per la chiusura di borsette e cartelle, per allacciare cinture e simili
ITMI950238A0 (it) Sistema per realizzare materiali similpelle tele incerate e simili producenti in superficie particolari effetti ottici e prodotti con esso ottenuti
IT1254061B (it) Test immunoenzimatico per la ricerca e determinazione degli anticorpi anti-ss-dna.
JPS644750A (en) Photoreceptive member
IT8129028V0 (it) Dispositivo di congiunzione, in particolare per la chiusura di borsette e cartelle, per allacciare cinture e simili

Legal Events

Date Code Title Description
EEER Examination request
MKEC Expiry (correction)

Effective date: 20131018